- Home
- ACIU vs GRX Comparison
ACIU vs GRX Comparison
Compare ACIU & GRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- GRX
- Stock Information
- Founded
- ACIU 2003
- GRX 2007
- Country
- ACIU Switzerland
- GRX United States
- Employees
- ACIU N/A
- GRX N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- GRX Finance/Investors Services
- Sector
- ACIU Health Care
- GRX Finance
- Exchange
- ACIU Nasdaq
- GRX Nasdaq
- Market Cap
- ACIU 173.7M
- GRX 154.8M
- IPO Year
- ACIU 2016
- GRX N/A
- Fundamental
- Price
- ACIU $1.68
- GRX $9.47
- Analyst Decision
- ACIU Strong Buy
- GRX
- Analyst Count
- ACIU 2
- GRX 0
- Target Price
- ACIU $10.00
- GRX N/A
- AVG Volume (30 Days)
- ACIU 137.1K
- GRX 39.7K
- Earning Date
- ACIU 04-30-2025
- GRX 01-01-0001
- Dividend Yield
- ACIU N/A
- GRX 5.98%
- EPS Growth
- ACIU N/A
- GRX N/A
- EPS
- ACIU N/A
- GRX 0.26
- Revenue
- ACIU $32,014,254.00
- GRX N/A
- Revenue This Year
- ACIU N/A
- GRX N/A
- Revenue Next Year
- ACIU $676.94
- GRX N/A
- P/E Ratio
- ACIU N/A
- GRX $38.50
- Revenue Growth
- ACIU 91.20
- GRX N/A
- 52 Week Low
- ACIU $1.43
- GRX $7.73
- 52 Week High
- ACIU $4.98
- GRX $10.40
- Technical
- Relative Strength Index (RSI)
- ACIU 46.75
- GRX 47.23
- Support Level
- ACIU $1.55
- GRX $9.55
- Resistance Level
- ACIU $1.79
- GRX $9.91
- Average True Range (ATR)
- ACIU 0.10
- GRX 0.14
- MACD
- ACIU 0.03
- GRX 0.02
- Stochastic Oscillator
- ACIU 66.67
- GRX 54.93
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.